Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
Price:
22.91 USD
3.85%
Market Closed
Updated:
May 15, 2024
Arrowhead Pharmaceuticals Inc
Pre-Tax Income
|
Arrowhead Pharmaceuticals Inc
Pre-Tax Income Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Arrowhead Pharmaceuticals Inc
NASDAQ:ARWR
|
Pre-Tax Income
-$478.1m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-27%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Pre-Tax Income
$6.3B
|
CAGR 3-Years
23%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-16%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Pre-Tax Income
$4.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Pre-Tax Income
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Pre-Tax Income
$4B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
See Also
What is Arrowhead Pharmaceuticals Inc's Pre-Tax Income?
Pre-Tax Income
-478.1m
USD
-478.1m
USD
Based on the financial report for Mar 31, 2024, Arrowhead Pharmaceuticals Inc's Pre-Tax Income amounts to -478.1m USD.
What is Arrowhead Pharmaceuticals Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
-27%
-27%
Over the last year, the Pre-Tax Income growth was -222%. The average annual Pre-Tax Income growth rates for Arrowhead Pharmaceuticals Inc have been -63% over the past three years , and -27% over the past ten years .
You don't have any saved screeners yet
